Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants
- Author:
Sang A KIM
1
;
Ho Young YHIM
;
Soo Mee BANG
Author Information
- Publication Type:Review
- Keywords: Cancer-associated Venous Thromboembolism; Low-Molecular-Weight Heparin; Direct Oral Anticoagulants
- MeSH: Animals; Anticoagulants; Cats; Comorbidity; Complementary Therapies; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Mortality; Pharmacokinetics; Population Characteristics; Recurrence; Renal Insufficiency; Thrombosis; Venous Thromboembolism; Vitamin K
- From:Journal of Korean Medical Science 2019;34(6):e52-
- CountryRepublic of Korea
- Language:English
- Abstract: Cancer-associated venous thromboembolism (CAT) is a common complication associated with high morbidity and mortality. In accordance with major clinical trials comparing low-molecular-weight heparin (LMWH) with a vitamin K antagonist (VKA), LMWH is currently the standard treatment for CAT, owing to its efficacy for thrombosis recurrence and improved safety profile compared to VKA. Over the past few years, direct oral anticoagulants (DOACs) have emerged as potential alternative therapies to LMWH due to their convenient route of administration and predictable pharmacokinetics, but evidence for their use in CAT is inconclusive, as only a small fraction of the study populations in these trials had CAT. Recently, two large head-to-head trials comparing DOACs to LMWH in CAT patients reported comparable efficacies of DOACs with increased bleeding risk. Occasionally, CAT treatment can be challenging due to the heterogeneity of underlying malignancies and comorbidities. Renal insufficiency and gastrointestinal defects are the main obstacles in anticoagulant selection. Careful choice of treatment candidates and proper anticoagulant strategies are critical for the treatment of CAT; hence, more studies are required to address these challenges.
